A Phase 3 interventional study of IVIG in Covid19 and Pneumonia, sponsored by Biopharma Plasma LLC. Completed at 9 sites in Ukraine. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-14.
Sponsored by Biopharma Plasma LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in COVID-19 with a site in Ukraine — 1 open to participants now, 1 under way, 1 of them phase 3. COVID-19 · Ukraine.
Among the 45 studies in COVID-19 with a site in Ukraine, this one is the 33rd largest by enrollment of the 39 interventional ones that give a count, is one of 15 that started in 2020, is one of 19 in phase 3, and was the 6th registered.
7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →1 of the 45 studies in COVID-19 with a site in Ukraine is open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Ukraine, United States, Argentina and 21 more countries
Ages 18+
A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 26 · Phase 4 3
First in 2020; this study’s year is marked. 15 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 285 across the 39 interventional studies, 1,003 across the 6 observational. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 45 have an industry lead sponsor. The 10 most frequent:
Biopharma Plasma LLC is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Biopharma Plasma LLC has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 45 studies in COVID-19 with a site in Ukraine, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Pneumonia caused by coronavirus infection COVID-19 is characterized by a combination of several dangerous factors that consistently worsen the patient's condition: viral lung damage early in the disease; a sharp increase in inflammation on the background of an unbalanced immune response ("cytokine storm"); joining a bacterial infection.
The condition of patients deteriorates significantly mostly at cytokine storm development. The damaging of a large volume of lung tissue leads to develops of respiratory failure, respiratory distress syndrome, or shock. Ventilatory support becomes ineffective and patients die.
There are reports of the effectiveness of Human Normal Immunoglobulin for Intravenous Administration (IVIG) high doses when used as part of complex therapy in patients with pneumonia caused by coronavirus COVID-19. In particular, IVIG has a positive effect on survival rates, overall disease course, duration of stay in the intensive care unit, and ventilatory support duration.
The probable mechanism of action of high-dose IVIG therapy is considered to be a regulatory effect on the immune system. Similar is the known and confirmed effectiveness of IVIG for autoimmune diseases (Kavasaky disease, Guillain Barre syndrome, Chronic inflammatory demyelinating polyradiculoneuropathy, Multifocal motor neuropathy).
This trial to assesses the Efficacy of IVIG (medication trade name - Bioven, manufactured by Biopharma Plasma LLC) in the High Immunomodulatory Dose in Complex Treatment of Severe Pneumonia Caused by COVID-19 / SARS-CoV-2
The screening stage:
The patient or his legal representative must sign an informed consent. After signing the informed consent, the screening tests\&procedures are performed and the compliance with the inclusion / non-inclusion criteria is assessed.
For patients who have been screened and meet the inclusion criteria and do not fall under the exclusion criteria, a blinded randomization procedure is provided.
Randomization is performed by the IVRS method, according to the blinded-block patient's randomization table.
The clinical stage of the trial:
Begins after patient randomization. At the clinical stage, among other things, provides:
Patients in the Control Group will receive therapy recommended by the COVID-19 coronavirus infection treatment protocol, depending on the severity of their condition according to the prescribing list, which will not include immunoglobulin preparations.
Patients of the Study Group (IVIG) receive high-dose therapy with the study drug (Bioven, 10% solution for infusions produced by Biopharma Plasma LLC, Ukraine). The dose is calculated by body weight. Patients will also receive therapy recommended by the COVID-19 coronavirus infection treatment protocol, depending on the severity of their condition according to the prescribing list.
Bioven administered intravenously, at an initial rate of 0.5 - 1.0 ml/kg body weight/hour for 30 minutes. In the absence of any undesirable side effects, the rate of administration can be gradually increased (recommended increase by 0.5 - 1.5 ml/kg body weight/hour every 10 minutes). According to results previously accomplished clinical studies, the maximum rate of Bioven administration is up to 8.5 ml/kg body weight/hour.
Observation and completion stage:
Begins and continues from the last administration of the study drug until the discharge of the patient from the hospital, but not less than 28 days from the confirmation of the diagnosis of pneumonia caused by coronavirus infection COVID-19.
The following procedures are provided at the stage:
The patient's condition is assessed daily till discharge; and by schedule after discharge (if it happen earlier), during 28 days period after diagnosis of severe pneumonia caused by coronavirus infection COVID-19 In case of death of the patient - the date and cause of death are fixed. The results of the study are evaluated by endpoints.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
severe pneumonia caused by COVID-19 according to the criteria below:
or if any of the conditions listed below have developed on the background of previously diagnosed coronavirus pneumonia:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive IVIG (trade name - Bioven) with base therapy
Drug: IVIG
Patients receive base therapy only
Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.
Also known as: Human normal immunoglobulin for intravenous administration, Bioven
Period duration (in days) to clinical improvement
Number of days post-onset of severe pneumonia to the moment of normalization at least two from following primary outcomes: O2 saturation with self-breathing, respiratory movements rate with self-breathing, body temperature without antipyretics use, lymphocyte count (targeted levels set in the description each of these primary outcomes)
Time frame: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 days
O2 saturation (SPO2 percentage), with self-breathing
The target level of SPO2 percentage - 95% and above with self-breathing, is used as one of the clinical improvement criteria
Time frame: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 days
Respiratory movements rate (amount per minute), with self-breathing
The target level of respiratory movements - 28 per minute or less with self-breathing, is used as one of the clinical improvement criteria
Time frame: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 days
Body temperature without antipyretics use
Measured in degrees Celsius. Fever absence (body temperature no more 37 degrees Celsius) during at least 24 hours without antipyretics, is used as one of the clinical improvement criteria.
Time frame: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 days
Lymphocyte count
The target level 1000 cells / mm3 and above is used as one of the clinical improvement criteria (applicable for patients with lymphocytes count lower 1000 cells / mm3 at screening moment)
Time frame: From date post-onset of severe pneumonia to date of patient discharge or date of death, whichever came first, assessed up to 28 days
Time from the onset of the disease to discharge, in days
Period duration (in days)
Time frame: 28 days
Duration of the need for ventilatory support, in days
Number of days with ventilatory support
Time frame: 28 days
Duration of the need for intensive care, in days
Number of days in the intensive care unit
Time frame: 28 days
Duration of need for oxygenation in days (SPO2 ≤ 93% with self-breathing)
Number of days with necessery of oxygenation support
Time frame: 28 days
The C-reactive protein (CRP) level
Measuring the analyte concentration in plasma (mg/L)
Time frame: Day 0 (screening), day 5, day 14, day 28
The tumor necrozis factor alpha (TNF-α) level
Measuring the analyte concentration in plasma (pg/mL)
Time frame: Day 0 (screening), day 5, day 14, day 28
The interleukin-1β (IL-1β) level
Measuring the analyte concentration in plasma (pg/mL)
Time frame: Day 0 (screening), day 5, day 14, day 28
The interleukin-6 (IL-6) level
Measuring the analyte concentration in plasma (pg/mL)
Time frame: Day 0 (screening), day 5, day 14, day 28
The D-dimer level
Measuring the analyte concentration in plasma (µg FEU/mL)
Time frame: Day 0 (screening), day 5, day 14, day 28
The Complement (C3 component) level
Measuring the analyte concentration in plasma (g/L)
Time frame: Day 0 (screening), day 5, day 14, day 28
The Circulating immune complexes level
Measuring the analyte concentration in plasma (U/mL)
Time frame: Day 0 (screening), day 5, day 14, day 28
The ferritin level
Analyte concentration in plasma (ng/mL)
Time frame: Day 0 (screening), day 5, day 14, day 28
The procalcitonin level
Analyte concentration in plasma (ng/mL)
Time frame: Day 0 (screening), day 5, day 14, day 28
IgG subtypes
The IgG-subtypes (IgG1-IgG4) concentration in plasma (mg/dL)
Time frame: Day 0 (screening), day 5, day 14, day 28
Survival assessment for a 28-day follow-up period since the onset of severe pneumonia
Survivealance estimation
Time frame: 28 days
Frequency of side effects
Number of participants with adverse reactions related by investigational drug as assessed by CTCАЕ v 4.0
Time frame: 28 days
Frequency of serious side effects
Number of participants with serious adverse reactions related by investigational drug as assessed by CTCАЕ v 4.0
Time frame: 28 days
Plan to share: Yes — After completion of the trial, results will be published. Access to parts CSR planned after the release of scientific publications
Supporting information: Clinical study report
Time frame: After trial result publication 3 months later
Access criteria: For specialists in medicine, pharmacy, scientists
No publications or documents are linked to this record.
Ran from May 2020 to primary completion in Sep 2020, 4 months.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 4 months is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Biopharma Plasma LLC